Cargando…

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there are approaching 100 in clinical development), many w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deonarain, Mahendra P., Yahioglu, Gokhan, Stamati, Ioanna, Pomowski, Anja, Clarke, James, Edwards, Bryan M., Diez-Posada, Soraya, Stewart, Ashleigh C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698822/ https://www.ncbi.nlm.nih.gov/pubmed/31544868 http://dx.doi.org/10.3390/antib7020016

Ejemplares similares

Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile
por: De Sordi, Luisa, et al.
Publicado: (2015)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate
por: Butt, Mohammed Adil, et al.
Publicado: (2017)

Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017)

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
por: Lambert, John M., et al.
Publicado: (2017)

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression
por: Pye, Hayley, et al.
Publicado: (2018)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability
por: Lambregts, Doenja M. J., et al.
Publicado: (2011)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016)

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
por: Kang, Xiuhua, et al.
Publicado: (2018)

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021)

Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
por: Mahmood, Iftekhar
Publicado: (2021)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs
por: Kumar, Amit, et al.
Publicado: (2018)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies
por: Procopiou, George, et al.
Publicado: (2022)

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
por: Nguyen, Toan D., et al.
Publicado: (2023)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism
por: Tumey, L. Nathan, et al.
Publicado: (2016)

Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions
por: Weggen, Jan Tobias, et al.
Publicado: (2023)

Those ADCs
Publicado: (1971)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors
por: Gymnopoulos, Marco, et al.
Publicado: (2019)

Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.
por: Deonarain, M. P., et al.
Publicado: (1998)

Corrigendum: Kinetic studies and CFD-based reaction modeling for insights into the scalability of ADC conjugation reactions
por: Weggen, Jan Tobias, et al.
Publicado: (2023)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC
por: Figueroa, Isabel, et al.
Publicado: (2018)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

ADC : analog-to-digital converter reference manual.

The Chemistry Behind ADCs
por: Kostova, Vesela, et al.
Publicado: (2021)

Evaluating the Scope of Malignant Bone Tumor Using ADC Measurement on ADC Map
por: Chen, Haisong, et al.
Publicado: (2019)

Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
por: Marcucci, Fabrizio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_10hje27ealn3p8tblrt6suhoba